oral CETP inhibitor

Ph. III candidate in cardiology

Signif. lipid lowering effect at 5 mg PO QD

Nat. Med.

Monash University, Clayton, AUNewAmsterdam Pharma B.V., Naarden, NL

obicetrapib chemical structure oral CETP inhibitor - Monash University, Clayton, AU NewAmsterdam Pharma B.V., Naarden, NL

Context. Obicetrapib (Monash University and NewAmsterdam Pharma) is an oral selective cholesteryl ester transfer protein (CETP) inhibitor being developed for dyslipidemia. Patients with high cardiovascular risk typically aim to…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: